Kolexia
Gastinne Thomas Hématologie
Gastinne Thomas
Hématologie
Hôpital Hôtel-Dieu Nantes
Nantes, France
276 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Lymphomes Maladie de Hodgkin Lymphome B Lymphome à cellules du manteau Lymphome malin non hodgkinien Lymphome B diffus à grandes cellules Récidive tumorale locale Tumeurs hématologiques Myélome multiple

Collaborateurs

Voir plus
Le Gouill Steven
Le Gouill Steven
Clcc Institut Curie, Paris, France
Moreau Philippe
Moreau Philippe
Hôpital Hôtel-Dieu Nantes, Nantes, France
Mahe Beatrice
Mahe Beatrice
Hôpital Hôtel-Dieu Nantes, Nantes, France
Dubruille Viviane
Dubruille Viviane
Hôpital Hôtel-Dieu Nantes, Nantes, France

Industries

Voir plus
Gilead
16 collaboration(s)
Dernière en 2023
BEIGENE
12 collaboration(s)
Dernière en 2023
Takeda Pharmaceutical
7 collaboration(s)
Dernière en 2023
Janssen
7 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
MorningLyte: A Phase III Randomized, Open-label, International, Multicenter Study Evaluating the Efficacy and Safety of Mosunetuzumab Plus Lenalidomide in Comparison to Anti-CD20 Monoclonal Antibody Plus Chemotherapy in Subjects With Previously Untreated FLIPI 2-5 Follicular Lymphoma
Essai Clinique (The Lymphoma Academic Research Organisation)   13 mars 2024
LyMa101: Phase II Study to Evaluate the Efficacy of Upfront Obinutuzumab in Mantle Cell Lymphoma Patients Treated by DHAP Followed by Autologous Transplantation Plus Obinutuzumab Maintenance Then MRD Driven Maintenance
Essai Clinique (The Lymphoma Academic Research Organisation)   13 mars 2024
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas: A Phase 1/2 Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
Essai Clinique (Constellation Pharmaceuticals)   15 février 2024
SYMPHONY-1: Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma
Essai Clinique (Epizyme, Inc.)   14 février 2024
Features and outcomes of patients admitted to the ICU for chimeric antigen receptor T cell-related toxicity: a French multicentre cohort.
Annals of intensive care   31 janvier 2024
DALY 2-EU: A Pivotal Phase II Randomised, Multi-centre, Open-label Study to Evaluate the Efficacy and Safety of MB-CART2019.1 Compared to SoC Therapy in Participants With r/r DLBCL, Who Are Not Eligible for HDC and ASCT
Essai Clinique (Miltenyi Biomedicine GmbH)   31 janvier 2024
Outcomes of Patients With Aggressive B-Cell Lymphoma After Failure of ...
Medscape   27 janvier 2024
BRUIN-MCL-321: A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Essai Clinique (Loxo Oncology, Inc.)   24 janvier 2024
LOC-R01: Randomized Phase IB/II Study of Escalating Doses of Lenalidomide and Ibrutinib in Association With R-MPV as a Targeted Induction Treatment for Patients Aged 18 to 60 (up to 65 for Phase II) With a Newly Diagnosed Primary Central Nervous System Lymphoma
Essai Clinique (Institut Curie)   10 janvier 2024
Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome. A DESCAR-T study.
Blood advances   04 janvier 2024